scholarly journals Mammalian Target of Rapamycin as a Rational Therapeutic Target for Breast Cancer Treatment

Oncology ◽  
2013 ◽  
Vol 84 (1) ◽  
pp. 43-56 ◽  
Author(s):  
Patricia Mucci LoRusso
Keyword(s):  
Breast Cancer ◽  
Cancer Treatment ◽  
Therapeutic Target ◽  
Mammalian Target Of Rapamycin ◽  
Breast Cancer Treatment ◽  
Target Of Rapamycin

Estrogen signaling: An emanating therapeutic target for breast cancer treatment

2019 ◽  
Vol 177 ◽  
pp. 116-143 ◽  
Author(s):  
Tanmay Saha ◽  
Subhajit Makar ◽  
Rayala Swetha ◽  
Gopichand Gutti ◽  
Sushil K. Singh
Keyword(s):  
Breast Cancer ◽  
Cancer Treatment ◽  
Therapeutic Target ◽  
Breast Cancer Treatment ◽  
Estrogen Signaling

Deletion of the amino acid transporter Slc6a14 suppresses tumour growth in spontaneous mouse models of breast cancer

2015 ◽  
Vol 469 (1) ◽  
pp. 17-23 ◽  
Author(s):  
Ellappan Babu ◽  
Yangzom D. Bhutia ◽  
Sabarish Ramachandran ◽  
Jaya P. Gnanaprakasam ◽  
Puttur D. Prasad ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Amino Acid ◽  
Mouse Models ◽  
Therapeutic Target ◽  
Tumour Growth ◽  
Mammalian Target Of Rapamycin ◽  
Amino Acid Transporter ◽  
Mtor Pathway ◽  
Target Of Rapamycin ◽  
Acid Transporter

Deletion of the amino acid transporter Slc6a14 in mice suppresses tumour growth in spontaneous models of breast cancer via interference with mammalian target of rapamycin (mTOR) pathway; this indicates an obligatory role for SLC6A14 in breast cancer, highlighting its potential as a therapeutic target.

scholarly journals Experimental, Clinical and Morphological Analysis of H-Ras Oncoproteins for Locally Advanced Breast Cancer

2019 ◽  
Vol 7 (19) ◽  
pp. 3153-3157 ◽  
Author(s):  
A. M. Zhumakayeva ◽  
K. D. Rakhimov ◽  
I. M. Omarova ◽  
L. I. Arystan ◽  
S. M. Adekenov
Keyword(s):  
Breast Cancer ◽  
Prognostic Factor ◽  
Cancer Treatment ◽  
Advanced Breast Cancer ◽  
Therapeutic Target ◽  
Locally Advanced Breast Cancer ◽  
Locally Advanced ◽  
Breast Cancer Treatment ◽  
Advanced Breast ◽  
Mutational Activation

BACKGROUND: Activated forms of Ras are enhanced in both breast cancer as well as the cell lines with EGFR and HER2 expression. Therefore, H-Ras could be activated in breast tumours in the absence of direct mutational activation of Ras itself and could contribute to 20-50% of the cases. Expression inhibition, signal transduction interruption from H-Ras to the nucleus could become a promising therapeutic target. AIM: The aim of this study was to investigate the clinical and morphological criteria of locally advanced breast cancer and the expression of H-Ras oncoprotein in patients who have been subjected to different regimens of farnesyltransferase inhibitor. METHODS: H-Ras status was assessed by immunohistochemistry (IHC). RESULTS: An association between the expressions of H-Ras and Her2/neu (p = 0.001) as well as the tumour proliferation index Ki-67 (p = 0.001) in patients with breast cancer was established. Analysis of the relationship between H-Ras expression showed a relatively strong association with progression-free survival both before the treatment (V = 0.47; p = 0.001) and after the treatment (V = 0.45; p = 0.001). These results may indicate the clinical applicability of H-Ras as a prognostic factor or serve as a therapeutic target for breast cancer treatment. CONCLUSION: These results could indicate the potential clinical application of H-Ras as a prognostic factor or a therapeutic target for breast cancer treatment.

scholarly journals Notch signaling as a therapeutic target for breast cancer treatment?

2011 ◽  
Vol 13 (3) ◽  
Author(s):  
Jianxun Han ◽  
Michael J Hendzel ◽  
Joan Allalunis-Turner
Keyword(s):  
Breast Cancer ◽  
Cancer Treatment ◽  
Notch Signaling ◽  
Therapeutic Target ◽  
Breast Cancer Treatment
Sign in / Sign up

Export Citation Format

Share Document